内镜医师腺瘤检出率与粪便免疫化学检测结直肠癌筛查后续轮次结肠镜检查中肿瘤检出的关联:SCREESCO随机对照试验的横断面分析
基于SCREESCO试验数据,纳入343例在首轮和第二轮(间隔2年)粪便免疫化学检测(FIT)阳性( cutoff ≥10 μg/g粪便)后接受结肠镜检查者,分析第二轮结肠镜检查中结直肠肿瘤检出的危险因素。首轮结肠镜阴性者(n=230)中,第二轮检出结直肠癌和进展期结直肠肿瘤(ACN)的比例分别为0.9%和8.3%。首轮内镜医师的腺瘤检出率(ADR)与第二轮ACN检出风险相关,中、高ADR相对于极低ADR的多变量OR分别为0.17(95%CI 0.02-0.79)和0.19(95%CI 0.04-0.86)。
要点
- 首轮结肠镜阴性者中,第二轮检出结直肠癌0.9%、进展期结直肠肿瘤8.3%。
- 首轮内镜医师中ADR相对于极低ADR,第二轮ACN检出OR为0.17(95%CI 0.02-0.79)。
- 首轮内镜医师高ADR相对于极低ADR,第二轮ACN检出OR为0.19(95%CI 0.04-0.86)。
核心结论
- 内镜医师的ADR对后续轮次结肠镜检查中ACN检出的影响,凸显了在FIT筛查项目中考虑ADR以优化首轮结肠镜后随访的重要性。
研究设计与样本
- 采用SCREESCO研究数据,对首轮和第二轮(间隔2年)FIT阳性( cutoff ≥10 μg/g粪便)后接受结肠镜检查的参与者进行横断面分析,共纳入343人。
主要发现
- 首轮结肠镜阴性者(n=230)中,第二轮结肠镜检出结直肠癌和ACN的比例分别为0.9%和8.3%。
- 首轮内镜医师的中ADR相对于极低ADR,第二轮ACN检出的多变量OR为0.17(95%CI 0.02-0.79)。
- 首轮内镜医师的高ADR相对于极低ADR,第二轮ACN检出的多变量OR为0.19(95%CI 0.04-0.86)。
临床怎么用
- 原文结论认为,在FIT筛查项目中考虑内镜医师的ADR对优化首轮结肠镜后随访很重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In colorectal cancer screening with the fecal immunochemical test (FIT), the optimal follow-up after first-round colonoscopy for a positive FIT, particularly after negative colonoscopy, is unknown. Therefore, using Screening of Swedish Colons (SCREESCO) study data, we aimed to elucidate the risk factors for the detection of colorectal neoplasia in second-round colonoscopy, which can affect recommendations for the optimal follow-up. METHODS: We performed a cross-sectional analysis using data from SCREESCO participants undergoing colonoscopy after a positive 2-stool FIT, with a positivity cutoff value of ≥10 μg/g feces, in both the first and second rounds separated by a 2-year interval. We assessed the associations between colorectal neoplasia detection in second-round colonoscopy and participant characteristics, FIT concentrations, first-round colonoscopy results, and endoscopists' adenoma detection rates (ADRs), which were categorized as very low, low, intermediate, and high. RESULTS: This study included 343 individuals. Despite negative first-round colonoscopies (n = 230), colorectal cancer and advanced colorectal neoplasia (ACN) were detected in 0.9% and 8.3% of participants in the second-round colonoscopy, respectively. An association was demonstrated between the first-round endoscopists' ADRs and the risk of second-round ACN detection. The multivariable odds ratios of the first-round intermediate and high ADRs, compared with the very low ADR, for second-round ACN detection were 0.17 (95% confidence interval [CI], 0.02-0.79) and 0.19 (95% CI, 0.04-0.86), respectively. CONCLUSIONS: The impact of endoscopists' ADRs on ACN detection in subsequent-round colonoscopies underscores the importance of considering ADR for optimal follow-up after first-round colonoscopy in an FIT-based screening program.
引用
- Sekiguchi M, Westerberg M, Löwbeer C, et al. Endoscopist adenoma detection rate associated with neoplasia detection during subsequent-round colonoscopy in fecal immunochemical test-based colorectal cancer screening: cross-sectional analysis of the SCREESCO randomized controlled trial. Gastrointest Endosc. 2025. PMID: 39914632. doi:10.1016/j.gie.2025.01.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。